JP2020532955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532955A5 JP2020532955A5 JP2020506983A JP2020506983A JP2020532955A5 JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5 JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- stranded nucleic
- chemically modified
- acid molecule
- modified double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146785A JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542043P | 2017-08-07 | 2017-08-07 | |
| US62/542,043 | 2017-08-07 | ||
| US201762558183P | 2017-09-13 | 2017-09-13 | |
| US62/558,183 | 2017-09-13 | ||
| PCT/US2018/045671 WO2019032619A1 (en) | 2017-08-07 | 2018-08-07 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146785A Division JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532955A JP2020532955A (ja) | 2020-11-19 |
| JP2020532955A5 true JP2020532955A5 (https=) | 2021-08-26 |
| JP7820909B2 JP7820909B2 (ja) | 2026-02-26 |
Family
ID=65271710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506983A Active JP7820909B2 (ja) | 2017-08-07 | 2018-08-07 | 化学修飾されたオリゴヌクレオチド |
| JP2023146785A Pending JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146785A Pending JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200215113A1 (https=) |
| EP (1) | EP3664817A4 (https=) |
| JP (2) | JP7820909B2 (https=) |
| CN (1) | CN111201024A (https=) |
| AU (1) | AU2018313149B2 (https=) |
| CA (1) | CA3070747A1 (https=) |
| WO (1) | WO2019032619A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| CN106061488B (zh) * | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| EP3862005A1 (en) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| CN115135765A (zh) * | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸 |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| CN112266911B (zh) * | 2020-08-27 | 2022-07-22 | 清华大学 | 核酸分子 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| JP2024529025A (ja) * | 2021-08-04 | 2024-08-01 | フィオ ファーマシューティカルズ コーポレーション | 化学修飾されたオリゴヌクレオチド |
| WO2023015264A1 (en) * | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023130021A1 (en) * | 2021-12-30 | 2023-07-06 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved delivery properties |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| US20260097120A1 (en) * | 2022-09-21 | 2026-04-09 | Phio Pharmaceuticals Corp. | Induction of stem-like activated t cells |
| WO2025101204A1 (en) * | 2023-11-08 | 2025-05-15 | Phio Pharmaceuticals Corp. | Intratumoral targeting of pd-1 |
| WO2025117786A1 (en) * | 2023-11-28 | 2025-06-05 | Phio Pharmaceuticals Corp. | Enhanced combination immune checkpoint inhibition therapy utilizing rnai |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP2342340A1 (en) * | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US8691971B2 (en) * | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| US9745574B2 (en) * | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP3495497B1 (en) * | 2011-04-28 | 2021-03-24 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
| CN106061488B (zh) * | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| AU2015301460B2 (en) * | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| CN107921147B (zh) * | 2015-05-05 | 2021-12-24 | 江苏命码生物科技有限公司 | 一种新的前体miRNA及其在肿瘤治疗中的应用 |
| EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
-
2018
- 2018-08-07 EP EP18843248.8A patent/EP3664817A4/en active Pending
- 2018-08-07 US US16/637,514 patent/US20200215113A1/en active Pending
- 2018-08-07 CN CN201880061531.8A patent/CN111201024A/zh active Pending
- 2018-08-07 WO PCT/US2018/045671 patent/WO2019032619A1/en not_active Ceased
- 2018-08-07 CA CA3070747A patent/CA3070747A1/en active Pending
- 2018-08-07 AU AU2018313149A patent/AU2018313149B2/en active Active
- 2018-08-07 JP JP2020506983A patent/JP7820909B2/ja active Active
-
2023
- 2023-09-11 JP JP2023146785A patent/JP2024028231A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532955A5 (https=) | ||
| US20230285538A1 (en) | Efficacious mrna vaccines | |
| JP6993649B2 (ja) | 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途 | |
| Udhayakumar et al. | Arginine‐rich peptide‐based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide | |
| US20210340543A1 (en) | Non-coding immunomodulatory dna construct | |
| US20220387585A1 (en) | Adoptive cell therapy using spherical nucleic acids (snas) | |
| JP2023179428A (ja) | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 | |
| JP5805088B2 (ja) | 遺伝子発現を阻害する組成物およびその使用 | |
| JP6083571B2 (ja) | 自己ゲル化核酸 | |
| JP2010515464A (ja) | Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法 | |
| US20200291394A1 (en) | Conjugation of peptides to spherical nucleic acids (snas) using traceless linkers | |
| MX2008008279A (es) | Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos. | |
| JP2023501445A5 (https=) | ||
| AU2018247308A1 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| CA3074113A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| KR20190134506A (ko) | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
| CN108431228A (zh) | Tlr抑制性寡核苷酸及其用途 | |
| KR101749230B1 (ko) | 지질-dna 및 면역 조절 물질을 포함하는 자기조립 나노구조체, 및 이를 유효성분으로 포함하는 암, 감염 질환 또는 면역 질환의 치료 또는 예방용 약제학적 조성물 | |
| CN108251421A (zh) | 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用 | |
| Duvanov | Selection of oligonucleotides specific to chicken peripheral blood mononuclear cells in whole blood ex vivo system |